SCHEMBL5260083

SCHEMBL5260083

N#Cc1cnc2cc3nn[nH]c3cc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 2/20 0.43
HTT P42858 1/20 0.33
CDC7 O00311 1/20 0.32
CYP19A1 P11511 1/20 0.31
RIPK1 Q13546 1/20 0.31
IMPDH2 P12268 1/20 0.30
IMPDH1 P20839 1/20 0.30
MAP4K4 O95819 1/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
METAP2 P50579 1/20 0.30
PKN1 Q16512 1/20 0.30
PKN2 Q16513 1/20 0.30
IDH1 O75874 1/20 0.30
RHEB Q15382 1/20 0.30
PDGFRB P09619 1/20 0.30
PDGFRA P16234 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5260088 0.94 HPGDS (0.43) HPGDSHTTCDC7IMPDH2IMPDH1
SCHEMBL5255547 0.76 HPGDS (0.44) HPGDSHTTRIPK1IMPDH2IMPDH1
SCHEMBL5255322 0.74 FABP6 (0.44) HPGDSHTTCDC7MAP4K4KDM4E
SCHEMBL5256282 0.73 HPGDS (0.50) HPGDSHTTCDC7MAP4K4KDM4E
SCHEMBL5309369 0.71 HPGDS (0.44) HPGDSHTTCYP19A1IMPDH2IMPDH1
SCHEMBL5255546 0.70 HPGDS (0.44) HPGDSHTTCDC7IMPDH2IMPDH1
SCHEMBL7773268 0.69 PIN1 (0.45) IMPDH2IMPDH1ALDH1A1METAP2PKN1
SCHEMBL203218 0.69 IMPDH2 (0.43) CYP19A1RIPK1IMPDH2IMPDH1KDM4E
SCHEMBL19250635 0.69 DYRK1A (0.53) HPGDSHTTCDC7RIPK1KDM4E
SCHEMBL19651897 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1242382-B1 TRICYCLIC PROTEIN KINASE INHIBITORS WYETH CORP (US) 2007-02-07 EP claimed
EP-1242382-B1 TRICYCLIC PROTEIN KINASE INHIBITORS WYETH CORP (US) 2007-02-07 EP disclosed
US-20060247217-A1 Tricyclic protein kinase inhibitors BERGER DAN M 2006-11-02 US disclosed
US-7105531-B2 Tricyclic protein kinase inhibitors WYETH (US) 2006-09-12 US disclosed
US-20040110762-A1 Tricyclic protein kinase inhibitors WYETH 2004-06-10 US disclosed
EP-1242382-A1 TRICYCLIC PROTEIN KINASE INHIBITORS Wyeth (US) 2002-09-25 EP disclosed
US-20010051620-A1 Tricyclic protein kinase inhibitors AMERICAN HOME PRODUCTS CORPORATION (US) 2001-12-13 US disclosed
WO-2001047892-A1 TRICYCLIC PROTEIN KINASE INHIBITORS WYETH (US) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110762-A1 Tricyclic protein kinase inhibitors CDK1, CDKN1A, CDK2 HPGDS 2439/4885HTT 3675/4885CDC7 53/4885
US-20060247217-A1 Tricyclic protein kinase inhibitors CDK1, CDKN1A, CDK2 HPGDS 2539/4885HTT 3724/4885CDC7 51/4885
US-20010051620-A1 Tricyclic protein kinase inhibitors CDK1, CHEK1, ABL1 HPGDS 3253/4885HTT 3920/4885CDC7 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.